CG
AIMT

Cutler Group’s Aimmune Therapeutics AIMT Stock Holding History

Cutler Group’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-2,800
Closed -$17K – 4964
2019
Q4 		$17K Buy
+2,800
New +$78.3K ﹤0.01% 2330
2019
Q2 		– Sell
-9,000
Closed -$4K – 5048
2019
Q1 		$4K Buy
9,000
+5,000
+125% +$118K ﹤0.01% 3117
2018
Q4 		$4K Sell
4,000
-7,000
-64% -$181K ﹤0.01% 3103
2018
Q3 		$24K Sell
11,000
-1,700
-13% -$48.1K ﹤0.01% 2137
2018
Q2 		$3K Sell
12,700
-6,400
-34% -$196K ﹤0.01% 3484
2018
Q1 		$62K Buy
19,100
+7,200
+61% +$253K 0.01% 1516
2017
Q4 		$76K Buy
11,900
+9,800
+467% +$316K ﹤0.01% 1561
2017
Q3 		$11K Sell
2,100
-10,400
-83% -$224K ﹤0.01% 3768
2017
Q2 		$23K Sell
12,500
-22,600
-64% -$431K ﹤0.01% 3293
2017
Q1 		$61K Buy
35,100
+30,700
+698% +$630K ﹤0.01% 2209
2016
Q4 		$23K Buy
+4,400
New +$89.9K ﹤0.01% 3341

Cutler Group's AIMT Position: Q4 2020 in Review

Cutler Group sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 300 shares — an estimated $10K sold.

Cutler Group first reported a position in AIMT in Q3 2016 and held it in 14 quarters. The position peaked at $193K in Q3 2018. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • Cutler Group reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Cutler Group sold 300 Aimmune Therapeutics shares in Q4 2020, an estimated $10K.
  • Cutler Group first reported a position in Aimmune Therapeutics in Q3 2016 and held it in 14 quarters.
  • Cutler Group's Aimmune Therapeutics position peaked at $193K in Q3 2018.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Cutler Group's 13F filing for Q4 2020, filed 21 Jan 2021.